LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

NCT04261387 | Completed Phase 1 FDA Drug

• 1 other identifier: LUT-RD-02-01
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 2

Brief Summary

The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically administered in breast cancer patients who developed radiation dermatitis. Subjects enrolled to part 1 will be enrolled to receive the study treatment (open label treatment) for 28 days and will be followed up for 2 months after the completion of study treatment. Subject in Part 2 will be randomized in 1:1 ratio to receive either the study drug or placebo (double-blind treatment) for qd topical application for 28 days and will be followed up for 2 months after the completion of study treatment.

Conditions

Radiation Dermatitis

Keywords

Radiation dermatitis, dermatitis, breast cancer

Outcome Measures

Primary Outcomes (2)

• Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE (Part 1 subjects)

  Common Terminology Criteria for Adverse Events Version 5.0

  12 weeks (83 days)

• Change in the severity of radiation dermatitis based on self reporting Dermatology QoL questionnaire (Part 2 subjects)

  Dermatology Life Quality Index questionnaire

  14 Days

Secondary Outcomes (4)

• Change in the severity of radiation dermatitis assessed by CTCAE (Part 1 subjects)

  12 weeks (83 days)

• Change in the severity of radiation dermatitis assessed by RTOG/EORTC (part 1 subjects)

  12 weeks (83 days)

• Change in the severity of radiation dermatitis based on self reporting Dermatology QoL questionnaire

  12 weeks (83 days)

• Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE (Part 2 subjects)

  12 weeks (83 days)

Study Arms (2)

LUT014 Gel

EXPERIMENTAL

LUT014 Gel topical application to the dermatitis area qd for 28 days

Drug: LUT014 Gel

Placebo for LUT014 Gel

PLACEBO COMPARATOR

Drug: Placebo for LUT014 Gel

Interventions

LUT014 Gel DRUG

Topical application qd for 28 days

LUT014 Gel

Placebo for LUT014 Gel DRUG

Matching placebo for qd topical application for 28 days

Placebo for LUT014 Gel

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female subjects diagnosed with stage Tis, T0-T3, N0-N2, M0 Breast Cancer;
• Subject is ≥18 years at the time of signing the informed consent form (ICF);
• Radiation dermatitis of Grade 2, based on the NCI CTCAE at the Screening and Baseline (D0) visits;
• Completed fractionated radiation therapy for breast prior to first dose of study drug (Day 0);
• A score of ≥ 6 reported in the Dermatology Life Quality Index at the Screening and Baseline Visits;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
• Females of child-bearing potential must have a negative pregnancy test at screening and must agree to use an effective contraception method\* or abstain from sex throughout the study until Day 83;
• Expected life expectancy greater than 6 months

You may not qualify if:

• Bilateral breast irradiation;
• Planned partial breast accelerated irradiation;
• Any cutaneous infection or significant skin disease at Screening or Baseline (Day 0) other than the dermatitis in the area(s) irradiated during fractionated radiation therapy;
• T4 breast cancer or direct skin involvement by breast cancer;
• Breast implants or underwent breast reconstruction;
• Any cancer other than breast cancer within 3 years of Screening, except for carcinoma in situ of the cervix;
• Pregnant or lactating;
• History of active systemic lupus erythematosus or scleroderma that is believed to increase the risk of developing radiation-induced dermatitis or its severity;
• Clinically significant co-morbid diseases
• Treatment with a serine/threonine-protein kinase B-Raf (B-Raf) inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), Braftovi® (encorafenib), and Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer;
• Treatment with a topical corticosteroid o the irradiated chest area within 14 days prior to Baseline (Day 0).
• Treatment with a systemic corticosteroid within 14 days prior to Baseline (Day 0), except for low dose systemic corticosteroids (e.g., 8-20 mg dexamethasone or comparable) given for up to one or two days every two weeks as part of standard of care for the prevention or treatment of chemotherapy-induced nausea and vomiting (CINV);
• Treatment with any investigational drug within 30 days or 5 half-lives of drug prior to Screening, whichever is longer;
• Known hypersensitivity to any of the inactive ingredients of the study drug.

Sponsors & Collaborators

• Lutris Pharma Ltd.: lead

Study Sites (2)

Columbus Regional Research Institute, Llc

Columbus, Georgia, 31901, United States

Location

Willis-Knighton Cancer Center

Shreveport, Louisiana, 71103, United States

Location

MeSH Terms

Conditions

Radiodermatitis; Dermatitis; Breast Neoplasms

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases; Radiation Injuries; Wounds and Injuries; Neoplasms by Site; Neoplasms; Breast Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 4, 2020
• First Posted: February 7, 2020
• Study Start: January 30, 2021
• Primary Completion: June 16, 2022
• Study Completion: July 15, 2022
• Last Updated: July 27, 2022

Record last verified: 2022-04

Locations

US (2)